文献速递乳腺癌

系列[18F]-FDHT-PET预测比卡鲁胺治疗AR阳性转移性乳腺癌疗效

Serial [18F]-FDHT-PET to predict bicalutamide efficacy in patients with androgen receptor positive metastatic breast cancer.
PubMed 文献 · Eur J Cancer · 2020-12-18

本研究评估[18F]-FDHT-PET检测比卡鲁胺治疗期间雄激素受体(AR)可用性变化及其与疗效相关性的可行性。21例AR阳性转移性乳腺癌患者基线及治疗4-6周后行PET,17例可评估者中位SUVcor从1.3降至0.7(P<0.001),但 tracer摄取降低不能预测比卡鲁胺疗效。

要点

  • 比卡鲁胺治疗4-6周后[18F]-FDHT摄取显著下降,反映AR占据。
  • 摄取下降幅度在疾病进展与临床获益患者间无显著差异(P=0.338)。
  • 该可行性研究未证实[18F]-FDHT-PET变化可预测比卡鲁胺疗效。

核心结论

  • 在AR阳性转移性乳腺癌患者中,随访[18F]-FDHT-PET可检测到比卡鲁胺诱导的示踪剂摄取降低,但该变化不能预测比卡鲁胺治疗反应。

研究设计与样本

  • 可行性研究,纳入21例AR阳性转移性乳腺癌患者(不限雌激素受体状态),基线及比卡鲁胺治疗4-6周后行[18F]-FDHT-PET,随访PET在17例患者349个病灶中可评估。

主要发现

  • 基线[18F]-FDHT-PET在21例患者中检出标准影像所见515个病灶中的341个,并发现21个新病灶。
  • 随访[18F]-FDHT-PET显示每患者及每病灶中位SUVcor从1.3降至0.7(P<0.001)。
  • 每患者中位摄取降低百分比为-45%,每病灶为-39%。
  • 疾病进展患者(n=11)中位降低百分比为-30%,临床获益患者(n=6,其中RECIST评估n=3、临床评估n=3)为-53%,P=0.338。

关键数值与推荐

  • 临床获益依据RECIST 1.1或临床评估(无疾病进展≥24周)判定。
  • 基线[18F]-FDHT摄取以最大标准化摄取值表示,变化以背景校正后的SUVcor百分比降低评估。

临床怎么用

  • [18F]-FDHT-PET可用于无创可视化AR并检测治疗中AR占据变化,但尚不能作为比卡鲁胺疗效预测工具。

局限性

  • 可行性研究样本量小(可评估17例),临床获益患者仅6例,统计效能有限。
  • 临床获益判定部分依赖临床评估而非RECIST,异质性可能影响结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The androgen receptor (AR) is a potential target in metastatic breast cancer (MBC), and 16β-[18F]-fluoro-5α-dihydrotestosterone positron emission tomography ([18F]-FDHT-PET) can be used for noninvasive visualisation of AR. [18F]-FDHT uptake reduction during AR-targeting therapy reflects AR occupancy and might be predictive for treatment response. We assessed the feasibility of [18F]-FDHT-PET to detect changes in AR availability during bicalutamide treatment and correlated these changes with treatment response. PATIENTS AND METHODS: Patients with AR + MBC, regardless of oestrogen receptor status, received an [18F]-FDHT-PET at baseline and after 4-6 weeks bicalutamide treatment. Baseline [18F]-FDHT uptake was expressed as maximum standardised uptake value. Percentage change in tracer uptake, corrected for background activity (SUVcor), between baseline and follow-up PET scan (% reduction), was assessed per-patient and lesion. Clinical benefit was determined in accordance with Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 or clinical evaluation (absence of disease progression for ≥24 weeks). RESULTS: Baseline [18F]-FDHT-PET in 21 patients detected 341 of 515 lesions found with standard imaging and 21 new lesions. Follow-up [18F]-FDHT-PET was evaluable in 17 patients with 349 lesions, showing a decrease in median SUVcor from 1.3 to 0.7 per-patient and lesion (P < 0.001). Median % reduction per-patient was -45% and per-lesion -39%. In patients with progressive disease (n = 11), median % reduction was -30% versus -53% for patients who showed clinical benefit (in accordance with RECIST (n = 3) or clinical evaluation (n = 3); P = 0.338). CONCLUSION: In this feasibility study, a bicalutamide-induced reduction in [18F]-FDHT uptake could be detected by follow-up [18F]-FDHT-PET in patients with AR + MBC. However, this change could not predict bicalutamide response. CLINICAL TRIAL INFORMATION: NCT02697032.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Boers J, Venema CM, de Vries EFJ, et al. Serial [18F]-FDHT-PET to predict bicalutamide efficacy in patients with androgen receptor positive metastatic breast cancer. Eur J Cancer. 2020. PMID: 33341447. doi:10.1016/j.ejca.2020.11.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。